Eisai Co Ltd Entered Into An Agreement With Gilead Sciences Inc

Eisai Co., Ltd. Entered Into An Agreement With Gilead Sciences, Inc. For The Commercialization And Distribution Of Filgotinib (Jyseleca), An Oral, Jak1 Preferential Inhibitor For Indications Of Rheumatoid Arthritis (Ra), Ulcerative Colitis, And Crohn'S Disease In Asia (South Korea, Taiwan, Hong Kong And Singapore). In December 2019, Eisai Signed A Partnership Agreement With Gilead Sciences K.K., A Japanese Subsidiary Of Gilead, For The Distribution And Co-Promotion Of Filgotinib In Japan. Under The Terms Of The New Agreement, Eisai Will Obtain An Exclusive Marketing Right For Filgotinib In South Korea, Taiwan, Hong Kong And Singapore From Gilead. Gilead Has Received Approval For The Treatment Of Ra In Taiwan And Has Applied For Approval Of Filgotinib For The Treatment Of Ra In South Korea. Following Approvals, Eisai Will Take Over The Manufacturing And Marketing Licenses For Filgotinib From Gilead In South Korea And Taiwan. In Hong Kong And Singapore, Eisai Will Apply For Approval For Filgotinib. With This Agreement, Eisai Will Pay Gilead A Contractual Up-Front Payment, As Well As Regulatory Milestones And Sales Milestones. Filgotinib Is A Once-Daily, Oral, Jak1 Preferential Inhibitor. In Japan, Filgotinib Has Been Approved For The Treatment Of Rheumatoid Arthritis (Including Prevention Of Structural Joint Damage) In Patients Who Have Had An Inadequate Response To Conventional Therapies. In April 2021, Gilead Sciences K.K. Applied For An Additional Indication Of Filgotinib As A Treatment For Patients With Moderate To Severe Active Ulcerative Colitis.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!